Mean half-lives of biologic agents licensed for use in Canada (June 2011). Retrieved from Health Canada Drug Product Database: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php.
| Mean Half-life, days | 2 Half-lives, days | 5 Half-lives, days | |
|---|---|---|---|
| Etanercept (ETN) | 4.3 | 8.6 | 21.5 |
| Adalimumab (ADA) | 14 | 28 | 70 |
| Infliximab (IFX) | 8–10 | 16–20 | 40–50 |
| Golimumab (GOL) | 12 | 24 | 60 |
| Certolizumab (CTZ) | 14 | 28 | 70 |
| Rituximab (RTX) | 21 | 42 | 105 |
| Abatacept (ABAT) | 13 | 26 | 65 |
| Tocilizumab (TCZ) | 13 | 26 | 65 |